Capricor Therapeutics(CAPR)
Focus: Capricor Therapeutics is a San Diego-based public biotech specializing in allogeneic cell and exosome-based therapies for rare diseases, particularly cardiac and muscular disorders. The company operates at a modest scale with ~$22M FY2025 revenue and an aggressive R&D focus.
Profile data last refreshed 4h ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Open Jobs
32+2 this month
Stable — net +2 jobs in 30d
6 added, 4 removed. Backfill posture.
Should You Work at Capricor Therapeutics?
AI assessmentCapricor offers early-career scientists a chance to shape rare-disease cell therapy but demands tolerance for high financial and clinical risk.
Why Work Here
- Lead role in cutting-edge cell therapy platform with 11 active trials spanning cardiology and rare muscle disease, including Phase 3 Deramiocel for Duchenne Muscular Dystrophy.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$22M
Pipeline & Clinical Trials
CAP-1002 Allogeneic Cardiosphere-Derived Cells
COVID-19Clinical Trials (1)
NCT04338347CAP-1002 in Severe COVID-19 Disease
N/AHelp build intelligence for Capricor Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.